A Novel Cu(II)-Binding Peptide Identified by Phage Display Inhibits Cu<SUP>2+</SUP>-Mediated A Aggregation

Xiaoyu Zhang,Xiancheng Zhang,Manli Zhong,Pu Zhao,Chuang Guo,You Li,He Xu,Tao Wang,Huiling Gao
DOI: https://doi.org/10.3390/ijms22136842
IF: 5.6
2021-01-01
International Journal of Molecular Sciences
Abstract:Copper (Cu) has been implicated in the progression of Alzheimer's disease (AD), and aggregation of Cu and amyloid beta peptide (A beta) are considered key pathological features of AD. Metal chelators are considered to be potential therapeutic agents for AD because of their capacity to reduce metal ion-induced A beta aggregation through the regulation of metal ion distribution. Here, we used phage display technology to screen, synthesize, and evaluate a novel Cu(II)-binding peptide that specifically blocked Cu-triggered A beta aggregation. The Cu(II)-binding peptide (S-A-Q-I-A-P-H, PCu) identified from the phage display heptapeptide library was used to explore the mechanism of PCu inhibition of Cu2+-mediated A beta aggregation and A beta production. In vitro experiments revealed that PCu directly inhibited Cu2+-mediated A beta aggregation and regulated copper levels to reduce biological toxicity. Furthermore, PCu reduced the production of A beta by inhibiting Cu2+-induced BACE1 expression and improving Cu(II)-mediated cell oxidative damage. Cell culture experiments further demonstrated that PCu had relatively low toxicity. This Cu(II)-binding peptide that we have identified using phage display technology provides a potential therapeutic approach to prevent or treat AD.
What problem does this paper attempt to address?